Get the Stockscreener App
12.13
0.08%
0.01
After Hours:
12.13
Xencor Inc stock is traded at $12.13, with a volume of 2.32M.
It is up +0.08% in the last 24 hours and up +6.31% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$12.12
Open:
$12.17
24h Volume:
2.32M
Relative Volume:
3.06
Market Cap:
$889.60M
Revenue:
$125.58M
Net Income/Loss:
$-92.14M
P/E Ratio:
-9.7634
EPS:
-1.2424
Net Cash Flow:
$-138.27M
1W Performance:
+1.08%
1M Performance:
+6.31%
6M Performance:
+17.88%
1Y Performance:
-9.95%
1-Day Range:
$11.79
$12.41
1-Week Range:
$11.34
$12.50
52-Week Range:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.13 | 888.86M | 125.58M | -92.14M | -138.27M | -1.2424 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Aug Analyst Calls: What hedge funds are buying Xencor IncLong Setup & Daily Price Action Insights - baoquankhu1.vn
Macro Review: Will Xencor Inc stock hit new highs in YEAR2026 Top Decliners & Fast Momentum Entry Tips - baoquankhu1.vn
Royalty rift: Alexion cuts off US royalty payments to Xencor - MSN
Retail Trends: Can Xencor Inc beat the S P 500Quarterly Growth Report & Expert Curated Trade Ideas - baoquankhu1.vn
Earnings Recap: Is Xencor Inc backed by strong institutional buying2026 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
Braidwell LP Lowers Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor, Inc. $XNCR Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Xencor’s Lung Cancer Trial Halted: What the Vudalimab Update Means for XNCR Investors - TipRanks
Jefferies Financial Group Inc. Takes Position in Xencor, Inc. $XNCR - MarketBeat
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans - Investing.com India
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans By Investing.com - Investing.com South Africa
(XNCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xencor at Leerink Global Healthcare: Strategic Development Insights - Investing.com Nigeria
Xencor, Genentech to End Protein Therapeutics Collaboration - The Globe and Mail
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xencor SVP Eckert sells $17,747 in shares - Investing.com Nigeria
Xencor faces royalty dispute with Alexion over Ultomiris sales - Investing.com Nigeria
Xencor (NASDAQ:XNCR) CEO Sells $72,798.12 in Stock - MarketBeat
John Desjarlais Sells 4,118 Shares of Xencor (NASDAQ:XNCR) Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Sells $19,472.34 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 3,244 Shares - MarketBeat
Xencor (NASDAQ:XNCR) VP Sells $27,572.04 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 14,870 Shares - MarketBeat
Xencor (XNCR) SVP and general counsel sells 5,011 shares for RSU tax - Stock Titan
Xencor (XNCR) CFO sells 2,517 shares to cover RSU tax withholding - Stock Titan
Xencor (XNCR) CEO sells 21,476 shares to cover RSU tax obligations - Stock Titan
Genentech ends Xencor (NASDAQ: XNCR) efbalropendekin alfa license deal - Stock Titan
Market Moves: What is the Moat Score of Xencor IncMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Xencor Inc a strong candidate for buy and hold2025 Top Decliners & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Breakouts: Can Xencor Inc disrupt its industry2025 Technical Patterns & Low Risk High Reward Ideas - baoquankhu1.vn
Insider Buy: Can Xencor Inc sustain its profitabilityJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Insider Bassil I. Dahiyat sells and vests shares (XNCR) — 12/19/2025 to 03/05/2026 - Stock Titan
Retail Trends: Is Xencor Inc impacted by rising rates2025 Historical Comparison & Consistent Profit Trading Strategies - baoquankhu1.vn
Resistance Check: What is the long term forecast for Xencor Inc stock2025 Key Highlights & Community Consensus Picks - baoquankhu1.vn
Xencor, Inc. $XNCR Shares Sold by Vanguard Group Inc. - MarketBeat
RBC Capital Reaffirms Their Buy Rating on Xencor (XNCR) - The Globe and Mail
Dahiyat, Xencor CEO, sells $80k in XNCR stock By Investing.com - Investing.com Australia
3,244-share sale planned by XNCR (NASDAQ: XNCR) — insider notice - Stock Titan
Insider sale and restricted vesting reported by Company (NASDAQ: XNCR) - Stock Titan
[144] Xencor Inc SEC Filing - Stock Titan
Xencor SVP Eckert sells $17,747 in shares By Investing.com - Investing.com Australia
Xencor faces royalty dispute with Alexion over Ultomiris sales By Investing.com - Investing.com Australia
Xencor (NASDAQ:XNCR) Shares Gap Down Following Insider Selling - MarketBeat
Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ) - Seeking Alpha
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor - Bitget
Xencor (NASDAQ:XNCR) VP Sells $31,689.70 in Stock - MarketBeat
Insider Selling: Xencor (NASDAQ:XNCR) SVP Sells 1,492 Shares of Stock - MarketBeat
Xencor sr. VP Desjarlais sells $31,676 in stock - Investing.com South Africa
Xencor sr. VP Desjarlais sells $31,676 in stock By Investing.com - Investing.com Canada
Dahiyat, Xencor CEO, sells $80k in XNCR stock - Investing.com
Xencor (NASDAQ: XNCR) CEO awarded options, sells stock for taxes - Stock Titan
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):